ClinicalTrials.gg
CompletedNCT01712451LIPO-102-CL-11Updated Mar 26, 2015

Dose-ranging Study

A Phase 2 interventional study of salmeterol xinafoate, fluticasone propionate and Placebo in Abdominal Contour Defects, sponsored by Neothetics, Inc. Completed at 6 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-26.

Sponsored by Neothetics, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Dose ranging study

02

Conditions studied

  • Abdominal Contour Defects

Browse trials for

Keywords

  • adiposity
03

In context

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 200 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Neothetics, Inc is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 45 years of age inclusive
  • abdominal contour defect
  • \<25 kg/msq
  • Stable diet and exercise and body weight

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of abdominal contour defects (liposuction, abdominoplasty, etc)
  • Known to study drugs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    LIPO-102, Low

    Drug: salmeterol xinafoate, fluticasone propionate

  • Experimental
    LIPO-102, Mid

    Drug: salmeterol xinafoate, fluticasone propionate

  • Experimental
    LIPO-102, High

    Drug: salmeterol xinafoate, fluticasone propionate

  • Experimental
    LIPO-102; Placebo

    Drug: Placebo

  • Experimental
    salmeterol xinafoate

    Drug: salmeterol xinafoate

Interventions

06

What researchers measure

Primary outcomes

  1. Safety

    physical exam, vital signs, clinical assessment of injection, clinical laboratory tests, and adverse events

    Time frame: 8 weeks treatment

  2. Change in abdominal circumference

    abdominal circumference

    Time frame: Baseline to 9 weeks

Secondary outcomes

  1. Change in global clinician scale score

    Time frame: Baseline to 9 weeks

  2. Change in global patient scale score

    Time frame: Baseline to 9 weeks

  3. Change in Photonumeric scale score

    Time frame: Baseline to 9 weeks

  4. Change in Patient Reported Outcome Score

    Time frame: Baseline to 9 weeks

07

Study locations

6 sites
  • Beverly Hills, California, United States
  • San Diego, California, United States
  • New York, New York, United States
  • Raleigh, North Carolina, United States
  • Nashville, Tennessee, United States
  • Plano, Texas, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 23, 2012
Start
Aug 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results delay requested
Mar 5, 2015
Last update
Mar 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01712451
Lead sponsor
Neothetics, Inc
Responsible party
Sponsor
First posted
Oct 23, 2012
Start date
Aug 2011
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Mar 26, 2015

Study contacts

Murray Maytom
study director · Neothetics, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone

Start the discussion